| Title |
New developments in the treatment of peripheral T-cell lymphoma – role of Belinostat
|
|---|---|
| Published in |
Cancer Management and Research, June 2015
|
| DOI | 10.2147/cmar.s85351 |
| Pubmed ID | |
| Authors |
Peter Reimer |
| Abstract |
Peripheral T-cell lymphomas (PTCL) represent a heterogeneous group of rare malignancies that with the exception of anaplastic lymphoma kinase expressing anaplastic large cell lymphoma, share a poor outcome after standard (eg, anthracycline-based) chemotherapy. Most patients are either refractory to initial therapy or eventually relapse. Randomized studies for relapsed/refractory PTCL are not available, however, recently published data show that conventional chemotherapy has very limited efficacy in the salvage setting. Thus, novel drugs are urgently needed to improve the outcome in this setting. Belinostat, a pan-histone deacetylase inhibitor, has demonstrated meaningful efficacy and a favorable toxicity profile in two single-arm Phase II trials on 153 patients with relapsed/refractory PTCL. The conclusive results led to an accelerated approval by the US Food and Drug Administration. The present review summarizes the clinical data available for belinostat, its current role, and future perspectives. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 17 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 3 | 18% |
| Student > Bachelor | 2 | 12% |
| Student > Doctoral Student | 2 | 12% |
| Student > Postgraduate | 2 | 12% |
| Student > Master | 2 | 12% |
| Other | 4 | 24% |
| Unknown | 2 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 53% |
| Agricultural and Biological Sciences | 2 | 12% |
| Nursing and Health Professions | 1 | 6% |
| Business, Management and Accounting | 1 | 6% |
| Social Sciences | 1 | 6% |
| Other | 1 | 6% |
| Unknown | 2 | 12% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 January 2019.
All research outputs
#7,430,186
of 25,584,565 outputs
Outputs from Cancer Management and Research
#323
of 2,067 outputs
Outputs of similar age
#81,972
of 281,752 outputs
Outputs of similar age from Cancer Management and Research
#3
of 11 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 2,067 research outputs from this source. They receive a mean Attention Score of 3.5. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 281,752 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.